PMID- 25674240
OWN - NLM
STAT- MEDLINE
DCOM- 20151030
LR  - 20181113
IS  - 1936-2625 (Electronic)
IS  - 1936-2625 (Linking)
VI  - 7
IP  - 12
DP  - 2014
TI  - Human epidermal growth factor receptor 2 expression in breast cancer: correlation 
      with clinical pathological features.
PG  - 8740-7
AB  - The overexpressed HER2 (human epidermal growth factor receptor 2) is a valuable 
      therapeutic target. Precise assessment of HER2 status is thus crucial in the 
      treatment of breast cancer. In this study, formalin-fixed, paraffin-embedded 
      samples of tumors from 304 breast cancer patients who underwent curative surgery 
      procedures between 2011 and 2014 were tested by immunohistochemistry (IHC) as a 
      primary estimate of HER2 status, followed by fluorescence in situ hybridization 
      (FISH). Concordance rate between IHC and FISH was evaluated. The Chi(2) test was 
      used to evaluate the correlation between HER2 gene amplification status and 
      different clinical pathological features including: (estrogen receptor) ER and 
      (progesterone receptor) PR expression, age, menopausal status and tumor size. The 
      results show that 84.8% of IHC score 3+ cases and 6.2% of IHC score 0/1+ cases 
      were amplified by FISH. After exclusion of group IHC 2+, the concordance rate 
      between FISH and IHC was 87.4%. There was a significant inverse association 
      between expression of hormone receptors (ER and PR) and HER2 amplification (P < 
      0.001) among the patients studied. However, no relationship was observed between 
      HER2 amplification and age, menopausal status and tumor size (P > 0.05). The data 
      demonstrate a relatively high level of concordance rate for HER2 testing between 
      FISH and IHC, and HER2 overexpression was associated with the levels of ER and 
      PR.
FAU - Ning, Shu-Fang
AU  - Ning SF
AD  - Department of Medical Research, Affiliated Tumor Hospital of Guangxi Medical 
      University Nanning, China.
FAU - Li, Ji-Lin
AU  - Li JL
AD  - Department of Medical Research, Affiliated Tumor Hospital of Guangxi Medical 
      University Nanning, China.
FAU - Luo, Cheng-Piao
AU  - Luo CP
AD  - Department of Pathology, Affiliated Tumor Hospital of Guangxi Medical University 
      Nanning, China.
FAU - Wei, Chang-Hong
AU  - Wei CH
AD  - Department of Pathology, Affiliated Tumor Hospital of Guangxi Medical University 
      Nanning, China.
FAU - Lu, Yong-Kui
AU  - Lu YK
AD  - Department of Chemotherapy, Affiliated Tumor Hospital of Guangxi Medical 
      University Nanning, China.
FAU - Liu, Hai-Zhou
AU  - Liu HZ
AD  - Department of Medical Research, Affiliated Tumor Hospital of Guangxi Medical 
      University Nanning, China.
FAU - Wei, Wen-E
AU  - Wei WE
AD  - Department of Medical Research, Affiliated Tumor Hospital of Guangxi Medical 
      University Nanning, China.
FAU - Zhang, Li-Tu
AU  - Zhang LT
AD  - Department of Medical Research, Affiliated Tumor Hospital of Guangxi Medical 
      University Nanning, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20141201
PL  - United States
TA  - Int J Clin Exp Pathol
JT  - International journal of clinical and experimental pathology
JID - 101480565
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor/*analysis
MH  - Breast Neoplasms/*genetics/metabolism/*pathology
MH  - Female
MH  - Gene Amplification
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Receptor, ErbB-2/*analysis/biosynthesis/genetics
MH  - Receptors, Estrogen/analysis/biosynthesis
MH  - Receptors, Progesterone/analysis/biosynthesis
MH  - Reproducibility of Results
PMC - PMC4314040
OTO - NOTNLM
OT  - Breast cancer
OT  - HER2
OT  - clinical pathological features
OT  - fluorescence in situ hybridization (FISH)
OT  - immunohistochemistry (IHC)
EDAT- 2015/02/13 06:00
MHDA- 2015/10/31 06:00
PMCR- 2014/12/01
CRDT- 2015/02/13 06:00
PHST- 2014/10/07 00:00 [received]
PHST- 2014/11/26 00:00 [accepted]
PHST- 2015/02/13 06:00 [entrez]
PHST- 2015/02/13 06:00 [pubmed]
PHST- 2015/10/31 06:00 [medline]
PHST- 2014/12/01 00:00 [pmc-release]
PST - epublish
SO  - Int J Clin Exp Pathol. 2014 Dec 1;7(12):8740-7. eCollection 2014.